Intelligence · Clinical pipeline
Infectious disease R&D Pipeline
Antiviral, antibacterial, and infectious disease vaccine pipeline programs.
Quick answer
Infectious disease: NovaPharmaNews indexes 1,112 infectious disease clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Antiviral, antibacterial, and infectious disease vaccine pipeline programs.
Top sponsors
- United Therapeutics Europe 94 programs
- BRIGHT MINDS BIOSCIENCES 81 programs
- Chinese Academy of 77 programs
- Sinovac Research and 49 programs
- GSK Glaxo Smith 39 programs
- Takeda 33 programs
- First People's Hospital 31 programs
- Vertex Pharmaceuticals (Australia) 30 programs
- Vir Biotechnology 26 programs
- George Institute for 25 programs
- ENANTA PHARMACEUTICALS 22 programs
- Hospital Authority 22 programs
Pipeline programs
-
Baricitinib
Eli Lilly Co.
Covid19 Corona Virus Infection
1 trial -
Behavioral Drug and HIV Risk Reduction Counseling
BRIGHT MINDS BIOSCIENCES INC.
Opiate Dependence
1 trial -
Bemnifosbuvir (BEM)
Atea Pharmaceuticals
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)
1 trial -
Bemnifosbuvir-Ruzasvir
Atea Pharmaceuticals
HEPATITIS C VIRUS CHRONIC INFECTION
1 trial -
Bemnifosbuvir-Ruzasvir (BEM/RZR)
Atea Pharmaceuticals
HEPATITIS C VIRUS CHRONIC INFECTION
1 trial -
Bepirovirsen
GlaxoSmithKline
Chronic Hepatitis B
1 trial -
Bictegravir
Gilead Sciences Ireland UC
HIV-1-infection
2 trials -
Brelovitug (BJT-778)
Mirum Pharmaceuticals International B.V.
Chronic Hepatitis D
1 trial -
Brelovitug 300 mg
Mirum Pharmaceuticals International B.V.
Chronic Hepatitis D Infection
3 trials -
Brincidofovir
Jazz Pharmaceuticals Ireland Limited
Adenovirus Infection
1 trial -
Buprenorphine/Naloxone
BRIGHT MINDS BIOSCIENCES INC.
HIV Infections
1 trial -
C4671026
Pfizer Australia Pty Ltd
SARS-CoV-2 Infection
1 trial -
C5091017
Pfizer Australia Pty Ltd
Covid-19 at high risk of progression to severe illness.
1 trial -
C5091018
Pfizer Australia Pty Ltd
Coronavirus Disease 2019 (COVID-19)
1 trial -
CARDIOL 100-03
Cardiol Therapeutics
COVID-19
1 trial -
CAZ-AVI
Pfizer
Complicated Intra-Abdominal Infection
1 trial -
CNBG-BIBP-O-2022003
Xiyuan Hospital of China Academy of Chinese Medical Sciences
COVID-19
2 trials -
COBI
Gilead Sciences Ireland UC
HIV
1 trial -
COVID-19 Vaccine,Inactivated
Sinovac Research and Development Co.,
COVID-19
1 trial -
CP101
Finch Therapeutics Group
Recurrent C. Difficile Infection
1 trial -
CPI-006 2 mg/kg + SOC
Corvus Pharmaceuticals
Covid-19
1 trial -
CVAY736B2201
Novartis Pharmaceuticals
Autoimmune hepatitis
1 trial -
Carraguard (PC-515)
United Therapeutics Europe Ltd
HIV Infections
2 trials -
Ceftaroline
Pfizer
Community-Acquired Bacterial Pneumonia
1 trial -
Ceftazidime - Avibactam ( CAZ-AVI)
Pfizer
Complicated Urinary Tract Infection
1 trial -
Ceftazidime-avibactam
Pfizer
Complicated Intra-abdominal Infection
1 trial -
Ceftriaxone
Adaptive Biotechnologies Corp
Community-acquired Pneumonia, Influenza, COVID-19
1 trial -
Cellulose Sulfate gel (6%)
United Therapeutics Europe Ltd
HIV Infection
1 trial -
Cervarix™
GlaxoSmithKline
Infections, Papillomavirus
1 trial -
Cetirizine
BRIGHT MINDS BIOSCIENCES INC.
COVID-19
1 trial -
Cholecalciferol (Vitamin D/Vigantol oil)
United Therapeutics Europe Ltd
Respiratory Tract Infections
1 trial -
Clesrovimab
Merck KGaA, Darmstadt, Germany
Respiratory Syncytial Virus Infection
1 trial -
Co-Trimoxazole 960Mg Dispersible Tablet
United Therapeutics Europe Ltd
Spontaneous Bacterial Peritonitis
1 trial -
D3 (Penta 21)
Fondazione Telethon ETS
HIV-infected
1 trial -
D7000C00001
AstraZeneca AB
COVID-19
1 trial -
DEXMEDETOMIDINE , 18F-DPA-714
Pari Pharma GmbH
Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.
1 trial -
DOR/ISL
Merck KGaA, Darmstadt, Germany
HIV Infection
1 trial -
DTG + 3TC
ViiV Healthcare B.V.
HIV Infections
1 trial -
DUO2025_01
Lacuna Pharma Pty Ltd
Complicated skin wounds (wounds healing per secundam via granulation tissue) - either as a complication of healing of acute wounds (infected surgical or traumatic wounds) or chronic wounds, in both cases infected with S. aureus and/or P. aeruginosa.
1 trial -
Daclatasvir
Bristol-Myers Squibb
Hepatitis C Virus Infection
2 trials -
Descovy or Truvada
BRIGHT MINDS BIOSCIENCES INC.
HIV Infections
1 trial -
Directly administered antiretroviral therapy (DAART)
BRIGHT MINDS BIOSCIENCES INC.
HIV Infections
2 trials -
Dociparstat sodium
Jazz Pharmaceuticals Ireland Limited
Coronavirus Disease 2019 (COVID-19)
1 trial -
Dolutegravir/abacavir/lamivudine FDC
ViiV Healthcare B.V.
Infection, Human Immunodeficiency Virus
1 trial -
Doxy-WISE
The George Institute
Sexually Transmitted Infections
1 trial -
Drotrecogin alfa (activated)
Eli Lilly and Company
Sepsis
1 trial -
Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment
United Therapeutics Europe Ltd
COVID19
1 trial -
EVO100
Evofem Biosciences
Chlamydia Trachomatis Infection
1 trial
Frequently asked questions
How many infectious disease pipeline programs are tracked?
1,112 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.